1.62
+0.04(+2.53%)
Currency In USD
| Previous Close | 1.58 |
| Open | 1.57 |
| Day High | 1.67 |
| Day Low | 1.55 |
| 52-Week High | 2.01 |
| 52-Week Low | 0.24 |
| Volume | 1.46M |
| Average Volume | 2.89M |
| Market Cap | 115.21M |
| PE | -3.24 |
| EPS | -0.5 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 0.78 |
| Change | 0.04 |
If you invested $1000 in Ovid Therapeutics Inc. (OVID) since IPO date, it would be worth $132.24 as of December 04, 2025 at a share price of $1.62. Whereas If you bought $1000 worth of Ovid Therapeutics Inc. (OVID) shares 5 years ago, it would be worth $604.48 as of December 04, 2025 at a share price of $1.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 03, 2025 11:05 AM GMT
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrantsNEW YORK, Oct. 03, 2025 (GLOBE NEWSWIR
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
GlobeNewswire Inc.
Oct 03, 2025 11:00 AM GMT
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vi